Targeted Therapies for Thymic Malignancies

被引：6

作者：

Girard, Nicolas ^{[1
,2
,3
]}

机构：

[1] Louis Pradel Hosp, Pilot Unit Management Rare Intrathorac Tumors, Dept Resp Med, F-69677 Lyon, France

[2] Univ Lyon 1, UMR 754, F-69007 Lyon, France

[3] Lyon Sud Hosp, Dept Radiotherapy, F-69495 Pierre Benite, France

来源：

THORACIC SURGERY CLINICS | 2011年 / 21卷 / 01期

关键词：

Thymoma; Thymic carcinoma; Epidermal growth factor receptor; Biology; KIT; Chemotherapy; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; CELL LUNG-CANCER; PROTEIN EXPRESSION; IMATINIB MESYLATE; MUTATIONAL STATUS; GENE-MUTATIONS; EGF-RECEPTOR; C-KIT; GEFITINIB;

D O I：

10.1016/j.thorsurg.2010.08.004

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Significant efforts have been made to dissect the molecular pathways involved in the carcinogenesis of thymic malignancies. Research is hampered by the rarity of the tumor, controversies about histopathologic classification, and the lack of established cell lines and animal models. Insights into the biology of these tumors have been made following anecdotal clinical responses to targeted therapies. This article reviews current knowledge about the molecular data that define molecular subsets and support the use of targeted therapies in thymic tumors.

引用

收藏

页码：115 / +

页数：10

相关论文

共 85 条

[1] Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone An Eastern Cooperative Oncology Group Study [J].

Aisner, Seena C. ;

Dahlberg, Suzanne ;

Hameed, Meera R. ;

Ettinger, David S. ;

Schiller, Joan H. ;

Johnson, David H. ;

Aisner, Joseph ;

Loehrer, Patrick J. .

JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) :885-892

[2] L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition [J].

Antonescu, Cristina R. ;

Busam, Klaus J. ;

Francone, Todd D. ;

Wong, Grace C. ;

Guo, Tianhua ;

Agaram, Narasimhan P. ;

Besmer, Peter ;

Jungbluth, Achim ;

Gimbel, Mark ;

Chen, Chin-Tung ;

Veach, Darren ;

Clarkson, Bayard D. ;

Paty, Philip B. ;

Weiser, Martin R. .

INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (02) :257-264

[3] Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma [J].

Azad, Arun ;

Herbertson, Rebecca A. ;

Pook, David ;

White, Shane ;

Mitchell, Paul L. R. ;

Tebbutt, Niall C. .

ACTA ONCOLOGICA, 2009, 48 (04) :619-621

[4] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].

Azzoli, Christopher G. ;

Baker, Sherman, Jr. ;

Temin, Sarah ;

Pao, William ;

Aliff, Timothy ;

Brahmer, Julie ;

Johnson, David H. ;

Laskin, Janessa L. ;

Masters, Gregory ;

Milton, Daniel ;

Nordquist, Luke ;

Pfister, David G. ;

Piantadosi, Steven ;

Schiller, Joan H. ;

Smith, Reily ;

Smith, Thomas J. ;

Strawn, John R. ;

Trent, David ;

Giaccone, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6251-6266

[5] A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma [J].

Bedano, P. M. ;

Perkins, S. ;

Burns, M. ;

Kessler, K. ;

Nelson, R. ;

Schneider, B. P. ;

Risley, L. ;

Dropcho, S. ;

Loehrer, P. J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[6] Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma [J].

Bisagni, Giancarlo ;

Rossi, Giulio ;

Cavazza, Alberto ;

Sartori, Giuliana ;

Gardini, Giorgio ;

Boni, Corrado .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (06) :773-775

[7]

BOS JL, 1989, CANCER RES, V49, P4682

[8] Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody [J].

Cao, Liang ;

Yu, Yunkai ;

Darko, Isaac ;

Currier, Duane ;

Mayeenuddin, Linnia H. ;

Wan, Xiaolin ;

Khanna, Chand ;

Helman, Lee J. .

CANCER RESEARCH, 2008, 68 (19) :8039-8048

[9]

Chakravarti A, 2002, CANCER RES, V62, P200

[10] Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer [J].

Chou, TY ;

Chiu, CH ;

Li, LH ;

Hsiao, CY ;

Tzen, CY ;

Chang, KT ;

Chen, YM ;

Perng, RP ;

Tsai, SF ;

Tsai, CM .

CLINICAL CANCER RESEARCH, 2005, 11 (10) :3750-3757

← 1 2 3 4 5 6 7 8 9 →